GlassScriptPhysician profile
Cary L Dunn
NPI 1639163298
$1,925.92
in general payments reported to CMS, 2019-2025
21 companies · $682 in 2025
The $682 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $256 · 2020: $183 · 2021: $55.72 · 2022: $153 · 2023: $79.54 · 2024: $517 · 2025: $682.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,278.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,278.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $624.40 | 2019-2025 | |
| Ucb, INC. | $173.46 | 2025 | Bimzelx |
| Dermavant Sciences, INC. | $144.37 | 2024 | Vtama |
| Revance Therapeutics, INC. | $144.32 | 2024 | Daxxify |
| Kerecis Limited | $134.05 | 2024-2025 | Kerecis Surgiclose, Kerecis Omega3 Marigen, Kerecis Graftguide |
| Organon LLC | $124.91 | 2025 | Vtama |
| Janssen Biotech, INC. | $118.67 | 2022-2025 | Tremfya |
| Incyte Corporation | $91.51 | 2024-2025 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $78.81 | 2021-2025 | Libtayo, Dupixent |
| Novartis Pharmaceuticals Corporation | $54.34 | 2025 | |
| Sun Pharmaceutical Industries INC. | $53.10 | 2020-2025 | |
| E.R. Squibb & Sons, L.L.C. | $29.21 | 2022-2023 | Sotyktu |
| Convatec INC. | $26.84 | 2023 | |
| Genzyme Corporation | $20.79 | 2020 | |
| Amgen INC. | $18.50 | 2024 | Otezla |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verrica Pharmaceuticals INC. | $17.59 | 2023 | Ycanth |
| Mallinckrodt Hospital Products INC. | $17.24 | 2025 | Acthar |
| Galderma Laboratories, L.P. | $14.26 | 2025 | Nemluvio |
| Leo Pharma INC. | $14.23 | 2019 | |
| Dermira, INC. | $13.24 | 2020 | |
| Mayne Pharma Commercial LLC | $12.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cary Dunn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.